DE10108851A1 - Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten - Google Patents
Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von InfektionskrankheitenInfo
- Publication number
- DE10108851A1 DE10108851A1 DE10108851A DE10108851A DE10108851A1 DE 10108851 A1 DE10108851 A1 DE 10108851A1 DE 10108851 A DE10108851 A DE 10108851A DE 10108851 A DE10108851 A DE 10108851A DE 10108851 A1 DE10108851 A1 DE 10108851A1
- Authority
- DE
- Germany
- Prior art keywords
- use according
- active
- resistance
- prodrugs
- substituted nucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002777 nucleoside Substances 0.000 title claims abstract description 17
- 125000003835 nucleoside group Chemical class 0.000 title claims abstract description 16
- 229940002612 prodrug Drugs 0.000 title claims abstract description 15
- 239000000651 prodrug Substances 0.000 title claims abstract description 15
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 title claims description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000013543 active substance Substances 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims description 13
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 8
- 201000004792 malaria Diseases 0.000 claims description 8
- 229960000485 methotrexate Drugs 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 208000004554 Leishmaniasis Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 5
- 230000003432 anti-folate effect Effects 0.000 claims description 4
- 229940127074 antifolate Drugs 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 239000004052 folic acid antagonist Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 3
- 150000005011 4-aminoquinolines Chemical class 0.000 claims description 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229960001444 amodiaquine Drugs 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 229960003677 chloroquine Drugs 0.000 claims description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims description 3
- 229960005385 proguanil Drugs 0.000 claims description 3
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims description 3
- 229960000611 pyrimethamine Drugs 0.000 claims description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 125000001174 sulfone group Chemical group 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 230000004544 DNA amplification Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 241000256186 Anopheles <genus> Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- 241001622982 Bombus soroeensis proteus Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001375804 Mastigophora Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000255129 Phlebotominae Species 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10108851A DE10108851A1 (de) | 2001-02-23 | 2001-02-23 | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
PCT/EP2002/001890 WO2002067951A2 (de) | 2001-02-23 | 2002-02-22 | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten |
JP2002567317A JP4194366B2 (ja) | 2001-02-23 | 2002-02-22 | 伝染病の無耐性治療のための5−置換型ヌクレオシド及び/又はプロドラッグの使用 |
AT02701291T ATE332141T1 (de) | 2001-02-23 | 2002-02-22 | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten |
AU2002234644A AU2002234644A1 (en) | 2001-02-23 | 2002-02-22 | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
US10/468,017 US7122528B2 (en) | 2001-02-23 | 2002-02-22 | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
DE50207436T DE50207436D1 (de) | 2001-02-23 | 2002-02-22 | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten |
EP02701291A EP1368040B1 (de) | 2001-02-23 | 2002-02-22 | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10108851A DE10108851A1 (de) | 2001-02-23 | 2001-02-23 | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10108851A1 true DE10108851A1 (de) | 2002-09-12 |
Family
ID=7675302
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE10108851A Ceased DE10108851A1 (de) | 2001-02-23 | 2001-02-23 | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten |
DE50207436T Expired - Fee Related DE50207436D1 (de) | 2001-02-23 | 2002-02-22 | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE50207436T Expired - Fee Related DE50207436D1 (de) | 2001-02-23 | 2002-02-22 | Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten |
Country Status (7)
Country | Link |
---|---|
US (1) | US7122528B2 (ja) |
EP (1) | EP1368040B1 (ja) |
JP (1) | JP4194366B2 (ja) |
AT (1) | ATE332141T1 (ja) |
AU (1) | AU2002234644A1 (ja) |
DE (2) | DE10108851A1 (ja) |
WO (1) | WO2002067951A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006037786A1 (de) * | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10313035A1 (de) * | 2003-03-24 | 2004-10-07 | Resprotect Gmbh | Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen |
GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
US20090068286A1 (en) * | 2007-09-11 | 2009-03-12 | Resprotect, Gmbh | Method of treating cancer by administration of 5-substituted nucleosides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19545892A1 (de) * | 1995-12-08 | 1997-06-12 | Fraunhofer Ges Forschung | Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1567001A (ja) | 1962-11-23 | 1969-05-16 | ||
GB1473148A (ja) | 1974-09-16 | 1977-05-11 | ||
US4902678A (en) | 1982-02-12 | 1990-02-20 | Syntex (U.S.A.) Inc. | Anti-viral compositions |
IT1170232B (it) | 1983-10-31 | 1987-06-03 | Anna Gioia Stendardi | Composizioni terapeutiche ad attivita' antivirale |
US4656260A (en) | 1984-12-27 | 1987-04-07 | Kanto Ishi Pharmaceutical Co., Ltd. | Cyclic pyrazolo C-nucleoside compound and process for preparing the same |
NL8700366A (nl) | 1987-02-13 | 1988-09-01 | Stichting Rega V Z W | Combinatie van fu met bvdu als middel tegen adenocarcinoom. |
GB8706176D0 (en) * | 1987-03-16 | 1987-04-23 | Wellcome Found | Therapeutic nucleosides |
US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
DK0806956T3 (da) | 1995-02-01 | 2003-01-06 | Resprotect Gmbh | Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling |
US6011000A (en) | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
CZ284920B6 (cs) | 1996-02-14 | 1999-04-14 | Vladimír Prof. Mudr. Drsc. Vonka | Preparáty pro léčbu rekurentního herpesu založené na potenciaci účinků syntetických virostatik kofeinem |
US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
US5831064A (en) | 1996-07-25 | 1998-11-03 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof |
DE69900841T2 (de) | 1998-01-23 | 2002-10-02 | Newbiotics Inc | Durch enzymkatalyse erhaltene therapeutische substanzen. |
-
2001
- 2001-02-23 DE DE10108851A patent/DE10108851A1/de not_active Ceased
-
2002
- 2002-02-22 EP EP02701291A patent/EP1368040B1/de not_active Expired - Lifetime
- 2002-02-22 WO PCT/EP2002/001890 patent/WO2002067951A2/de active IP Right Grant
- 2002-02-22 DE DE50207436T patent/DE50207436D1/de not_active Expired - Fee Related
- 2002-02-22 AT AT02701291T patent/ATE332141T1/de not_active IP Right Cessation
- 2002-02-22 AU AU2002234644A patent/AU2002234644A1/en not_active Abandoned
- 2002-02-22 JP JP2002567317A patent/JP4194366B2/ja not_active Expired - Fee Related
- 2002-02-22 US US10/468,017 patent/US7122528B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19545892A1 (de) * | 1995-12-08 | 1997-06-12 | Fraunhofer Ges Forschung | Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006037786A1 (de) * | 2006-08-11 | 2008-03-20 | Resprotect Gmbh | Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung |
US8492537B2 (en) | 2006-08-11 | 2013-07-23 | Resprotect Gmbh | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy |
Also Published As
Publication number | Publication date |
---|---|
WO2002067951A2 (de) | 2002-09-06 |
AU2002234644A1 (en) | 2002-09-12 |
JP2004526713A (ja) | 2004-09-02 |
EP1368040A2 (de) | 2003-12-10 |
ATE332141T1 (de) | 2006-07-15 |
US7122528B2 (en) | 2006-10-17 |
EP1368040B1 (de) | 2006-07-05 |
US20040127454A1 (en) | 2004-07-01 |
DE50207436D1 (de) | 2006-08-17 |
WO2002067951A3 (de) | 2003-03-20 |
JP4194366B2 (ja) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60310377T2 (de) | Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung | |
DE60011391T2 (de) | Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen | |
DE60130023T2 (de) | Behandlung der nebenwirkungen von statinen | |
DE60216139T3 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
DE60037578T2 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
DE60202278T2 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
EP0240829A2 (de) | Cancerostatisches Mittel | |
DE202009019087U1 (de) | Pharmazeutische Zusammensetzungen mit wünschenswerter Bioverfügbarkeit | |
DE68917186T2 (de) | Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie. | |
DE69634074T2 (de) | Thiole zur Förderung des Wachstums von Hömatopoietischen Vorläuferzellen | |
DE60038106T3 (de) | Anthelmintische zusammensetzungen | |
EP0001796A1 (de) | Mittel gegen Malaria | |
EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
DE60120928T2 (de) | Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung | |
CH713711B1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Infektionskrankheiten. | |
EP0374096A1 (de) | 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür | |
DE3873603T2 (de) | Zusammensetzung gegen coccidiosis. | |
DE10108851A1 (de) | Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten | |
DE69819900T2 (de) | Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil | |
DE10030781A1 (de) | Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen | |
EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
DE3780343T2 (de) | Antivirale 8-phenylxanthine. | |
EP0820770A2 (de) | Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und ein Antioxidans enthält | |
DE602004012731T2 (de) | Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben | |
EP0820771A2 (de) | Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8131 | Rejection |